The cyclin-dependent kinase inhibitor p21 CDKN1A as a target of anti-cancer drugs

Current Cancer Drug Targets

Volumn 12, Issue 2, 2012, Pages 85-96

  Stivala, L A ^a   Cazzalini, O ^a   Prosperi, E ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Anti cancer target, CDK inhibitor, cell cycle regulator, p21 CDKN1A

Indexed keywords

ANTINEOPLASTIC AGENT; BELINOSTAT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DACINOSTAT; DEPSIPEPTIDE; EPOXOMICIN; FK 288; GIVINOSTAT; LACTACYSTIN; MG 115; PANOBINOSTAT; ROMIDEPSIN; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL CYCLE REGULATION; CELL MOTILITY; DNA REPAIR; DNA REPLICATION; DRUG EFFICACY; DRUG INDICATION; DRUG TARGETING; GENE THERAPY; GLIOBLASTOMA; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; SOLID TUMOR; THYMOMA; THYMUS CANCER; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; NEOPLASMS;

EID: 84856446634     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800912799095126     Document Type: Review

References (156)

1. Harper, J. W.; Adami, G.; Wei, N.; Keyomarsi, K.; Elledge, S. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclindependent kinases. Cell 1993, 75, 805-816.
2. el-Deiry, W.; Tokino, T.; Velculescu, V. E.; Levy, D. B.; Parsons, R.; Trent, J. M.; Lin, D.; Mercer, W. E.; Kinzier, K. W. Volgestein, B. WAF1, a potential mediator of p53 tumor suppressor. Cell 1993, 75, 817-825.
3. Noda, A.; Ning, Y.; Venalle, S. F.; Pereira-Smith, O. M.; Smith, J. R. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 1994, 211, 90-98.
4. Roninson, I. B. Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1), association with cell senescence and tumour-promoting activities of stromal fibroblasts. Cancer Lett. 2002, 179, 1-14.
5. Brugarolas, J.; Moberg, K.; Boyd, S. D.; Taya, Y.; Jacks, T.; Lees, J. A. Inhibition of cyclin-dependent kinase 2 by p21 is necessary for retinoblastoma protein-mediated G1 arrest after gammairradiation. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 1002-1007.
6. Waldman, T.; Kinzler, K. W.; Vogelstein, B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 1995, 55, 5187-5190.
7. el-Deiry, W. S.; Harper, J. W.; O'Connor, P. M.; Velculescu, V. E.; Canman, C. E.; Jackman, J.; Pietenpol, J. A.; Burrell, M.; Hill, D. E.; Wang, Y.; Wiman, K. G.; Mercer, W. E.; Kastan, M. B.; Kohn, K. W.; Elledge, S. J.; Kinzler, K. W.; Vogelstein, B. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 1994, 54, 1169-1174.
8. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82, 675-684.
9. Brugarolas, J.; Chandrasekaran, C.; Gordon, J. I.; Beach, D.; Jacks, I.; Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 1995, 377, 552-557.
10. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J. P.; Sedivy, J. M.; Kinzler, K. W.; Vogelstein, B. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282, 1497-1501.
11. Cip1/Waf1 at both the G2/S and the G1/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol. Cell Biol. 1998, 18, 629-643.
12. Waldman, T.; Lengauer, C.; Kinzler, K. W.; Vogelstein, B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996, 381, 713-716.
13. WAF1/Cip1 functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9089-9094.
14. cip1/waf1. Science 2000, 287, 1804-1808.
15. Kippin, T. E.; Martens, D. J.; van der Kooy, D. p21 loss compromises the relative quiescence of forebrain stem cell proliferation leading to exhaustion of their proliferation capacity. Genes Dev. 2005, 19, 756-767.
16. Cip1 restricts neuronal proliferation in the subgranular zone of the dentate gyrus of the hyppocampus. Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 1358-1363.
17. Choudhury, A. R.; Ju, Z.; Djojosubroto, M. W.; Schienke, A.; Lechel, A.; Schaetzlein, S.; Jiang, H.; Stepczynska, A.; Wang, C.; Buer, J.; Lee, H. W.; von Zglinicki, T.; Ganser, A.; Schirmacher, P.; Nakauchi, H.; Rudolph, K. L. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat. Genet. 2007, 39, 99-105.
18. Viale, A.; De Franco, F.; Orleth, A.; Cambiaghi, V.; Giuliani, V.; Bossi, D.; Ronchini, C.; Ronzoni, S.; Muradore, I.; Monestiroli, S.; Gobbi, A.; Alcalay, M.; Minucci, S.; Pelicci, P. G. Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature 2009, 45, 751-756.
19. Herbig, U.; Sedivy, J. M. Regulation of growth arrest in senescence: telomere damage is not the end of the story. Mech. Ageing Dev. 2006, 127, 16-24.
20. CDKN1A impairs entry to quiescence and activates a DNA damage response in normal fibroblasts induced to quiescence. Cell Cycle 2009, 8, 105-114.
21. Bedelbaeva, K.; Snyder, A.; Gourevitch, D.; Clark, L.; Zhang, X. M.; Leferovich, J.; Cheverud, J. M.; Lieberman, P.; Heber-Katz, E. Lack of p21 expression links cell cycle control and appendage regeneration in mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 5845-5850.
22. Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 1998, 280, 1069-1072.
23. (WAF1/CIP1) expression is induced in newly nondividing cells in diverse epithelia and during differentiation of the Caco-2 intestinal cell line. Exp. Cell Res. 1996, 227, 171-181.
24. Casini, T.; Pelicci, P. G. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene 1999, 18, 3235-3243.
25. (KIP2) control muscle differentiation at the myogenin step. Genes Dev. 1999, 13, 213-224.
26. Cip-1/SDI-1/WAF-1 gene is involved in chondrogenic differentiation of ATDC5 cells in vitro. J. Biol. Chem. 2001, 276, 33249-33256.
27. Zezula, J.; Casaccia-Bonnefil, P.; Ezhevsky, S. A.; Osterhout, D. J.; Levine, J. M.; Dowdy, S. F.; Chao, M. V.; Koff, A. p21cip1 is required for the differentiation of oligodendrocytes independently of cell cycle withdrawal. EMBO Rep. 2001, 2, 27-34.
28. Weil, M.; Raff, M. C.; Braga, V. M. Caspase activation in the terminal differentiation of human epidermal keratinocytes. Curr. Biol. 1999, 9, 361-364.
29. Taulés, M.; Rodríguez-Vilarrupla, A.; Rius, E.; Estanyol, J. M.; Casanovas, O.; Sacks, D. B.; Pérez-Payá, E.; Bachs, O.; Agell, N. Calmodulin binds to p21(Cip1) and is involved in the regulation of its nuclear localization. J. Biol. Chem. 1999, 274, 24445-24448.
30. LaBaer, J.; Garrett, M. D.; Stevenson, L. F.; Slingerland, J. M.; Sandhu, C.; Chou, H. S.; Fattaey, A.; Harlow, E. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997, 11, 847-862.
31. Abukhdeir, A. M.; Park, B. H. p21 and p27, roles in carcinogenesis and drug resistance. Expert. Rev. Mol. Med. 2008, 10, e19.
32. Abbas, T.; Dutta, A. p21 in cancer, intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9, 400-414.
33. Moldovan, G. L.; Pfander, B.; Jentsch, S. PCNA, the maestro of replication fork. Cell 2007, 129, 665-679.
34. Prosperi, E. The fellowship of the rings, distinct pools of proliferating cell nuclear antigen (PCNA) trimer at work. FASEB J. 2006, 20, 833-837.
35. Waga, S.; Stilmann, B. Cyclin-dependent kinase inhibitor p21 modulates the DNA primer-template recognition complex. Mol. Cell Biol. 1998, 18, 4177-4187.
36. CDKN1A does not interfere with loading of PCNA at DNA replication sites, but inhibits subsequent binding of DNA polymerase δ at the G1/S phase transition. Cell Cycle 2003, 2, 596-603.
37. Gottifredi, V.; McKinney, K.; Poyurovsky M. V.; Prives, C. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J. Biol. Chem. 2004, 279, 582-5810.
38. WAF1 to promote DNA repair. Cell 2003, 114, 599-610.
39. Cazzalini, O.; Scovassi, A. I.; Savio, M.; Stivala, L. A.; Prosperi, E. Multiple roles of the cell cycle inhibitor p21(CDKN1A) in the DNA damage response. Mutat. Res. Rev. Mutat. 2010, 704, 12-20.
40. (CDKN1A) with PCNA regulates the histone acetyltransferase activity of p300 in nucleotide excision repair. Nucleic Acids Res. 2008, 36, 1713-1722.
41. Cazzalini, O.; Donà, F.; Savio, M.; Tillhon, M.; Maccario, C.; Perucca, P.; Stivala, L. A.; Scovassi, A. I.; Prosperi, E. p21CDKN1A participates in base excision repair by regulating the activity of poly(ADP-ribose) polymerase-1. DNA Repair 2010, 9, 627-635.
42. Avkin, S.; Sevilya, Z.; Toube, L.; Geacintov, N.; Chaney, S. G.; Oren, M.; Livneh, Z. p53 and p21 regulate error-prone DNA repair to yield a lower mutation load. Mol. Cell 2006, 22, 407-413.
43. Soria, G.; Speroni, J; Podhajcer, O. L.; Prives, C.; Gottifredi V. p21 differentially regulates DNA replication and DNA-repairassociated processes after UV irradiation. J. Cell Sci. 2008, 121, 3271-3282.
44. WAF1/Cip1: more than a break to the cell cycle? Biochim. Biophys. Acta 2000, 1471, M43-M56.
45. Coqueret, O. New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. 2003, 13, 65-70.
46. (WAF1/CIP1/SDI1). Cell Cycle 2002, 1, 39-41.
47. waf1 binds to the myc and cdc25A promoters upon DNA damage and induces transcriptional repression. J. Biol. Chem. 2006, 281, 34742-34750.
48. Fritah, A.; Saucier, C.; Mester, J.; Redeuilh, G.; Sabbah, M. p21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha. Mol. Cell. Biol. 2005, 25, 2419-2430.
49. WAF1/CIP1 induction of transactivation. Mol. Cell. Biol. 2000, 20, 2676-2686.
50. Los, M.; Stroh, C.; Janicke, R. U.; Engels, I. H.; Schulze-Osthoff, K. Caspase, more than just killers? Trends Immunol. 2001, 22, 31-34.
51. Gartel, A. L.; Tyner, A. L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol. Cancer Ther. 2002, 1, 639-649.
52. Datto, M. B.; Yu, Y.; Wang, X. F. Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. J. Biol. Chem. 1995, 270, 28623-28628.
53. Xu, S. Q.; El-Deiry, W. S. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem. Biophys. Res. Commun. 2000, 269, 179-190.
54. Suzuki, A.; Tsutomi, Y.; Akahane, K.; Araki, T.; Miura, M. Resistance to Fas-mediated apoptosis: activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998, 17, 931-939.
55. Suzuki, A.; Tsutomi, Y.; Miura, M.; Akahane, K. Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene 1999, 18, 1239-1244.
56. Harvey, K. J.; Lukovic, D.; Ucker, D. S. Caspase-dependent Cdk activity is a requisite effector of apoptotic death events. J. Cell. Biol. 2000, 148, 59-72.
57. Gartel, A. L.; Radhakrishnan, S. K. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005, 65, 3980-3985.
58. Fotedar, R.; Brickner, H.; Saadatmandi, N.; Rousselle, T.; Diederich, L.; Munshi, A.; Jung, B.; Reed, J. C.; Fotedar, A. Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells. Oncogene 1999, 18, 3652-3658.
59. Kondo, S.; Barna, B. P.; Kondo, Y.; Tanaka, Y.; Casey, G.; Liu, J.; Morimura, T.; Kaakaji, R.; Peterson, J. W.; Werbel, B.; Barnett, G. H. WAF1/CIP1 increases the susceptibility of p53 non-functional malignant glioma cells to cisplatin-induced apoptosis. Oncogene 1996, 13, 1279-1285.
60. Lincet, H.; Poulain. L.; Remy, J. S.; Deslandes, E.; Duigou, F.; Gauduchon, P.; Staedel, C. The p21(cip1/waf1) cyclin-dependent kinase inhibitor enhances the cytotoxic effect of cisplatin in human ovarian carcinoma cells. Cancer Lett. 2000, 161, 17-26.
61. Kang, K. H.; Kim, W. H.; Choi, K. H. p21 promotes ceramideinduced apoptosis and antagonizes the antideath effect of Bcl-2 in human hepatocarcinoma cells. Exp. Cell. Res. 1999, 253, 403-412.
62. Tsao, Y. P.; Huang, S. J.; Chang, J. L.; Hsieh, J. T.; Pong, R. C.; Chen, S. L. Adenovirus-mediated p21(WAF1/SDII/CIP1) gene transfer induces apoptosis of human cervical cancer cell lines. J. Virol. 1999, 73, 4983-4990.
63. Hingorani, R.; Bi, B.; Dao, T.; Bae, Y.; Matsuzawa, A.; Crispe, I. N. CD95/Fas signaling in T lymphocytes induces the cell cycle control protein p21cip-1/WAF-1, which promotes apoptosis. J. Immunol. 2000, 164, 4032-4036.
64. Göke, R.; Göke, A.; Göke, B.; El-Deiry, W. S.; Chen, Y. Pioglitazone inhibits growth of carcinoid cells and promotes TRAIL-induced apoptosis by induction of p21waf1/cip1. Digestion 2001, 64, 75-80.
65. Chinery, R.; Brockman, J. A.; Peeler, M. O.; Shyr, Y.; Beauchamp, R. D.; Coffey, R.J. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer; a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat. Med. 1997, 3, 1233-1241.
66. Giansanti, V.; Torriglia, A.; Scovassi A. I. Conversation between apoptosis and autophagy, "Is it your turn or mine?" Apoptosis 2011, 16, 321-333.
67. Fujiwara, K.; Daido, S.; Yamamoto, A.; Kobayashi, R.; Yokoyama, T.; Aoki, H.; Iwado, E.; Shinojima, N.; Kondo, Y.; Kondo, S. Pivotal role of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 in apoptosis and autophagy. J. Biol. Chem. 2008, 283, 388-397.
68. Cip1 is involved in Rasinduced inhibition of the ROCK/LIMK/Cofilin pathway. J. Biol. Chem. 2004, 279, 1885-1891.
69. LRR-1 targets a CDK inhibitor for cell cycle control in C. elegans and actin-based motility regulation in human cells. Dev. Cell. 2010, 19, 753-764.
70. Orend, G.; Hunter, T.; Ruoslahti, E. Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorageindependent cells. Oncogene 1998, 16, 2575-2583.
71. Mueller S.; Cadenas, E.; Schönthal, A. H. p21WAF1 regulates anchorage-independent growth of HCT116 colon carcinoma cells via E-cadherin expression. Cancer Res. 2000, 60, 156-163.
72. CDKN1A-GFP fusion protein during cell cycle arrest. Histochem. Cell. Biol. 2004, 121, 377-381.
73. Abella, N.; Brun, S.; Calvo, M.; Tapia, O.; Weber, J. D.; Berciano, M. T.; Lafarga, M.; Bachs, O.; Agell, N. Nucleolar disruption ensures nuclear accumulation of p21 upon DNA damage. Traffic 2010, 11, 743-755.
74. Suzuki, A.; Tsutomi, Y.; Yamamoto, N.; Shibutani, T.; Akahane, K. Mitochondrial regulation of cell death: mitochondria are essential for procaspase 3-p21 complex formation to resist Fasmediated cell death. Mol. Cell. Biol. 1999, 19, 3842-3847.
75. Asada, M.; Yamada, T.; Ichijo, H.; Delia, D.; Miyazono, K.; Fukumuro, K.; Mizutani, S. Apoptosis inhibitory activity of cytoplasmic p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 1999, 18, 1223-1234.
76. Zhou, B. P.; Liao, Y.; Xia, W.; Spohn, B.; Lee, M. H.; Hung, M. C. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell. Biol. 2001, 3, 245-252.
77. Li, Y.; Dowbenko, D.; Lasky. L. A. AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. J. Biol. Chem. 2002, 277, 11352-11361.
78. Zhang, Y.; Wang, Z.; Magnuson, N. S. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol. Cancer Res. 2007, 5, 909-922.
79. Scott, M. T.; Morrice, N.; Ball, K. L. Reversible phosphorylation at the C-terminal regulatory domain of p21(Waf1/Cip1) modulates proliferating cell nuclear antigen binding. J. Biol. Chem. 2000, 275, 11529-11537.
80. Rodríguez-Vilarrupla, A.; Díaz, C.; Canela, N.; Rahn, H. P.; Bachs, O.; Agell, N. Identification of the nuclear localization signal of p21(cip1) and consequences of its mutation on cell proliferation. FEBS Lett. 2002, 531, 319-323.
81. Waf1/Cip1. Oncogene 2010, 29, 2262-2271.
82. Wu, S.; Huang, S.; Ding, J.; Zhao, Y.; Liang, L.; Liu, T.; Zhan, R.; He, X. Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region. Oncogene 2010, 29, 2302-2308.
83. Jung, Y.-S.; Qian, Y.; Chen, X. Examination of the expanding pathways for the regulation of p21 expression. Cell Signalling 2010, 22, 1003-1012.
84. Child, E. S.; Mann, D. J. The intricacies of p21 phosphorylation. Protein/protein interactions, subcellular localization and stability. Cell Cycle 2006, 5, 1313-1319.
85. Soria, G.; Gottifredi, V. PCNA-coupled p21 degradation after DNA damage: the exception that confirms the rule? DNA Repair 2010, 9, 358-364.
86. Skp2 ubiquitin ligase in the degradation of p21Cip1 in S phase. J. Biol. Chem. 2003, 278, 25752-25757.
87. Cip1 by phosphorylation. J. Biol. Chem. 2002, 277, 29792-29802.
88. Cortés-Canteli, M.; Pignatelli, M.; Santos, A.; Perez-Castillo, A. CCAAT/enhancer-binding protein beta plays a regulatory role in differentiation and apoptosis of neuroblastoma cells. J. Biol. Chem. 2002, 277, 5460-5767.
89. WAF1/CIP1 expression. Biochem. Biophys. Res. Commun. 1996, 227, 564-569.
90. WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome. EMBO J. 2001, 20, 2367-2375.
91. waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 2003, 22, 6365-6377.
92. Waf1 via a conformational change. J. Biol. Chem. 2010, 24, 18407-18414.
93. Chen, X.; Chi, Y.; Bloecher, A.; Aebersold, R.; Clurman, B. E.; Roberts, J. M. N-acetylation and ubiquitin-independent proteasomal degradation of p21(Cip1). Mol. Cell. 2004, 16, 839-847.
94. WAF1/CIP1-deficient mice. Cancer Res. 2001, 61, 6234-6238.
95. Jackson, R. J.; Adnane, J.; Coppola, D.; Cantor, A.; Sebti, S. M.; Pledger, W. J. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 2002, 21, 8486-8497.
96. Cip1 nullizygosity increases tumor formation in irradiated mice. Cancer Res. 2003, 63, 3021-3025.
97. Chen, K,; Xia, W.; Yang, J. Y.; Hsu, J. L.; Chou, C.-K.; Sun, H.-L.; Wyszomierski, L. S.; Mills, G. B.; Muller, W. J.; Yu, D.; Hung, M.-C. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem. Biophys. Res. Commun. 2010, 403, 103-107.
98. Weinberg, W. C.; Fernandez-Sala, E.; Morgan, D. L.; Shalizi, A.; Mirosh, E.; Stanulis, E.; Deng, C.; Hennings, H.; Yuspa, S. H. Genetic deletion of p21WAF1 enhances papilloma formation but not malignant conversion in experimental mouse skin carcinogenesis. Cancer Res. 1999, 59, 2050-2054.
99. Poole, A. J.; Heap, D.; Carroll, R. E.; Tyner, A. L. Tumor suppressor functions for the Cdk inhibitor p21 in the mouse colon. Oncogene 2004, 23, 8128-8134.
100. -/- mice. Am. J. Pathol. 2005, 166, 1239-1246.
101. WAF1/cip1 gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res. 2001, 61, 565-569.
102. Balomenos, D.; Martìn-Caballero, J.; Garcìa, M. I.; Prieto, I.; Flores, J. M.; Serrano, M.; Martinez, A. C. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat. Med. 2000, 6, 171-176.
103. Albanese, P.; Chagraoui, J.; Charon, M.; Cocault, L.; Dusanter-Fourt, I.; Romeo, P. H.; Uzan, G. Forced expression of p21 in GPIIb-p21 transgenic mice induces abnormalities in the proliferation of erythroid and megakaryocyte progenitors and primitive hematopoietic cells. Exp. Hematol. 2002, 30, 1263-1272.
104. Wang, Y.; Cui, F.; Lv, Y.; Li, C.; Xu, X.; Deng, C.; Wang, D.; Sun, Y.; Hu, G.; Lang, Z.; Huang, C.; Yang, X. HBsAg and HBx knocked into the p21 locus causes hepatocellular carcinoma in mice. Hepatology 2004, 39, 318-24.
105. CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997, 277, 831-834.
106. Stivala, L. A.; Riva, F.; Cazzalini, O.; Savio, M.; Prosperi, E. p21(waf1/cip1)-null human fibroblasts are deficient in nucleotide excision repair downstream the recruitment of PCNA to DNA repair sites. Oncogene 2001, 20, 563-570.
107. Soto Martinez, J. L.; Cabrera Morales, C. M.; Serrano-Ortega, S.; Lopez-Nevot, M. A. Mutation and homozygous deletion analyses of genes that control the G1/S transition of the cell cycle in skin melanoma, p53, p21, p16 and p15. Clin. Transl. Oncol. 2005, 7, 156-164.
108. WAF1/CIP1 in malignant melanoma, reduced expression in metastatic lesions. Am. J. Pathol. 1996, 149, 1813-1822.
109. WAF1/CIP1 cyclin dependent kinase inhibitor gene, association with human esophageal cancer. Oncogene 2000, 19, 323-328.
110. Kibel, A. S.; Suarez. B. K.; Belani, J.; Oh, J.; Webster, R.; Brophy-Ebbers, M.; Guo, C.; Catalogna, W. J.; Picus, J.; Goodfellow, P. J. CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res. 2003, 63, 2033-2036.
111. WAF1, CIP1, SDI1 mutant (Arg94-->Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J. Biol. Chem. 1996, 271, 15782-15786.
112. WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res. 2003, 5, R242-R249.
113. Marshall, C. B.; Kroff, R. R.; Pippin, J. W.; Shankland, S. J. CDK inhibitor p21 is prosurvival in adriamycin-induced podocyte injury, in vitro and in vivo. Am. J. Physiol. Renal Physiol. 2010, 298, F1140-F1151.
114. Woods, J. M.; Klosowska, K.; Spoden, D. J.; Stumbo, N. G.; Paige, D. J.; Scatizzi, J. C.; Volin, M. V.; Rao, M. S.; Perlman, H. A cellcycle independent role for p21 in regulating synovial fibroblast migration in rheumatoid arthritis. Arthritis Res. Ther. 2006, 8, R113.
115. Yang, H.; Wang, S. W.; Yin, H. J. p21(WAF1) Gene Transfection Inhibits Proliferation of Leukemia Cell Line K562. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2001, 9, 115-118.
116. Drummond, D. C.; Noble, C. O.; Kirpotin, D. B.; Guo, Z.; Scott, G. K.; Benz, C. C. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 2005, 45, 495-528.
117. Mercurio, C.; Minucci, S.; Pelicci, P. G. Histone deacetylases and epigenetic therapies of hematological malignancies Pharmacol. Res. 2010, 62, 18-34.
118. Voorhees, P. M.; Orlowski, R. Z. The proteasome and proteasome inhibitors in cancer therapy. Annu. Rev. Pharmacol. Toxicol. 2006, 46, 189-213.
119. Zavrski, I.; Jakob, C.; Kaiser, M.; Fleissner, C.; Heider, U.; Sezer, O. Molecular and clinical aspects of proteasome inhibition in the treatment of cancer. Recent Results Cancer Res. 2007, 176, 165-176.
120. WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 1241-1246.
121. Pécuchet, N.; Cluzeau, T.; Thibault, C.; Mounier, N.; Vignot S. Histone deacetylase inhibitors: highlight on epigenetic regulation. Bull. Cancer 2010, 97, 917-935.
122. Zupkovitz, G.; Grausenburger, R.; Brunmeir, R.; Senese, S.; Tischler, J.; Jurkin, J.; Rembold, M.; Meunier, D.; Egger, G.; Lagger, S.; Chiocca, S.; Propst, F.; Weitzer, G.; Seiser, C. The cyclin-dependent kinase inhibitor p21 is a crucial target for histone deacetylase 1 as a regulator of cellular proliferation. Mol. Cell. Biol. 2010, 30, 1171-1181.
123. Ocker, M.; Schneider-Stock, R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int. J. Biochem. Cell Biol. 2007, 39, 1367-1374.
124. Kahnberg, P.; Lucke, A. J.; Glenn, M. P.; Boyle, G. M.; Tyndall, J. D. A.; Parson, P. G.; Fairlie, D. P. Design, synthesis, potency, and cytoselectively of anticancer agents derived by parallel synthesis from alpha-aminosuberic acid. J. Med. Chem. 2006, 49, 7611-7622.
125. Glaser, K. B. HDAC inhibitors: clinical update and mechanismbased potential. Biochem. Pharmacol. 2007, 74, 659-671.
126. Piekarz, R. L.; Robey, R. W.; Zhan, Z.; Kayastha, G.; Sayah, A.; Abdeldaim, A. H.; Torrico, S.; Bates, S. E. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004, 103, 4636-4643.
127. Vinodhkumar, R.; Song, Y. S.; Devaki, T. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Biomed. Pharmacother. 2008, 62, 85-93.
128. Lai, M. T.; Yang, C. C.; Lin, T. Y.; Tsai, F. J.; Chen, W. C. Depsipeptide (FK228) inhibits growth of human prostate cancer cells. Urol. Oncol. 2008, 26, 182-189.
129. Panicker, J.; Li, Z.; McMahon, C.; Sizer, C.; Steadman, K.; Piekarz, R.; Bates, S. E.; Thiele, C. J. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells. Cell Cycle 2010, 9, 1830-1838.
130. Buckley, M. T.; Yoon, J.; Yee, H.; Chiriboga, L.; Liebes, L.; Ara, G.; Qian, X.; Bajorin, D. F.; Sun, T. T.; Wu, X. R.; Osman, I. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J. Transl. Med. 2007, 5, 49.
131. Zhao, X.; Yang, W.; Shi, C.; Ma, W.; Liu, J.; Wang, Y.; Jiang, G. The G1 phase arrest and apoptosis by intrinsic pathway induced by valproic acid inhibit proliferation of BGC-823 gastric carcinoma cells. Tumour Biol. 2011, 32, 335-346.
132. Wedel, S.; Hudak, L.; Seibel. J. M.; Juengel, E.; Tsaur, I.; Wiesner, C.; Haferkamp, A.; Blaheta, R. A. Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci. 2011, 88, 418-424.
133. Gan, C. P.; Hamid, S.; Hor, S. Y.; Zain, R. B.; Ismail, S. M.; Wan Mustafa, W. M.; Teo, S. H.; Saunders, N.; Cheong, S. C. Valproic acid: Growth inhibition of head and neck cancer by induction of terminal differentiation and senescence. Head Neck 2011, Mar 24. doi: 10.1002/hed.21734.
134. Maiso, P.; Carvajal-Vergara, X.; Ocio, E. M.; López-Pérez, R.; Mateo, G.; Gutiérrez, N.; Atadja, P.; Pandiella, A.; San Miguel, J. F. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res. 2006, 66, 5781-5789.
135. Golay, J.; Cuppini, L.; Leoni, F.; Micò, C.; Barbui, V.; Domenghini, M.; Lombardi, L.; Neri, A.; Barbui, A. M.; Salvi, A.; Pozzi, P.; Porro, G.; Pagani, P.; Fossati, G.; Mascagni, P.; Introna, M.; Rambaldi, A. G. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells. Leukemia 2007, 21, 1892-1900.
136. Batty, N.; Malouf, G. G.; Issa, J. P. J. Histone deacetylase as antineoplastic agents. Cancer Lett. 2009, 280, 192-200.
137. Takay, N.; Narahara, H. Histone deacetylase inhibitor therapy in epithelial ovarian cancer. J. Oncol. 2010, 2010, 458431.
138. Tan, J.; Cang, S.; Ma, Y.; Petrillo, R. L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as ancti-cancer agents. J. Hematol. Oncol. 2010, 3, 5.
139. Matta, H.; Chaudhary, P. M. The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells. Cancer Biol. Ther. 2005, 4, 77-82.
140. Wang, Y.; Rishi, A. K.; Puliyappadamba, V. T.; Sharma, S.; Yang, H.; Tarca, A.; Ping Dou, Q.; Lonardo, F.; Ruckdeschel, J. C.; Pass, H. I.; Wali, A. Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother. Pharmacol. 2010, 66, 455-466.
141. Ludwig, H.; Khayat, D.; Giaccone, G.; Facon, T. Proteasome inhibition and its clinical prospects in the treatment of hematological and solid malignancies. Cancer 2005, 104, 1794-1807.
142. Russo, A.; Bronte, G.; Fulfaro, F.; Cicero, G.; Adamo, V.; Gebbia, N.; Rizzo, S. Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr. Cancer Drug Targets 2010, 10, 55-67.
143. Wu, W. K.; Sung, J. J.; Yu, L.; Cho, C. H. Proteasome inhibitor MG-132 lowers gastric adenocarcinoma TMK1 cell proliferation via bone morphogenetic protein signaling. Biochem. Biophys. Res. Commun. 2008, 371, 209-214.
144. Stoll, S. J.; Pitt, S. C.; Chen, H. Follicular thyroid cancer cell growth inhibition by proteosome inhibitor MG132. J. Surg. Res. 2009, 156, 39-44.
145. Villalonga-Planells, R.; Coll-Mulet, L.; Martinez-Soler, F.; Castaño, E.; Acebes, J. J.; Gimenez-Bonafè, P.; Gil, J.; Tortosa, A. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme. PLoS One 2011, 6, e18588.
146. Park, E. J.; Kondratyuk, T. P.; Morrell, A.; Kiselev, E.; Conda-Sheridan, M.; Cushman, M.; Ahn, S.; Choi, Y.; White, J. J.; van Breemen, R. B.; Pezzuto, J. M. Induction of retinoid X receptor activity and consequent upregulation of p21WAF1/CIP1 by indenoisoquinolines in MCF7 cells. Cancer Prev. Res. 2011, 4, 592-607.
147. Zhao, X.; Yang, L.; Hu, J. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. J. Exp. Clin. Cancer Res. 2011, 30, 55.
148. Gartel, A. L. Is p21 an oncogene? Mol. Cancer Ther. 2006, 5, 1385-1386.
149. WAF1/CIP1 as a therapeutic target in breast and other cancers. Cancer Cell 2003, 4, 425-429.
150. Fan, S.; Chang, J. K.; Smith, M. L.; Duba, D.; Fornace, A. J. Jr.; O'Connor, P. M. Cells lacking CIP1/WAF1 gene exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 1997, 14, 2127-2136.
151. Freemerman, A. J.; Vrana, J. A.; Tombes, R. M.; Jiang, H.; Chellappan, S. P.; Fisher, P. B.; Grant, S. Effects of antisense p21 (WAF1/CIP1/MDA6) expression on the induction of differentiation and drug-mediated apoptosis in human myeloid leukemia cells (HL-60). Leukemia 1997, 11, 504-513.
152. Park, S. H.; Park, J. Y.; Weiss, R. H. Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. J. Urol. 2008, 180, 352-360.
153. Fan, Y.; Borowsky, A. D.; Weiss, R. H. An antisense oligodeoxynucleotide to p21(Waf1/Cip1) causes apoptosis in human breast cancer cells. Mol. Cancer Ther. 2003, 2, 773-782.
154. Lazzarini, R.; Moretti, S.; Orecchia, S.; Betta, P. G.; Procopio, A.; Catalano, A. Enhanced antitumor therapy by inhibition of p21waf1 in human malignant mesothelioma. Clin. Cancer Res. 2008, 14, 5099-5107.
155. Koster, R.; di Pietro, A.; Timmer-Bosscha, H.; Gibcus, J. H.; van den Berg, A.; Suurmeijer, A. J.; Bischoff, R.; Gietema, J. A.; de Jong, S. Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J. Clin. Invest. 2010, 120, 3594-3605.
156. Park, S. H.; Wang, X.; Liu, R.; Lam, K. S.; Weiss, R. H. High throughput screening of a small molecule one-bead-one-compound combinatorial library to identify attenuators of p21 as chemotherapy sensitizers. Cancer Biol. Ther. 2008, 7, 2015-2022.